Durvalumab versus sugemalimab as consolidation therapy after definitive chemoradiotherapy for unresectable stage III non–small-cell lung cancer: a real-world comparative effectiveness study
Durvalumab versus sugemalimab as consolidation therapy after definitive chemoradiotherapy for unresectable stage III non–small-cell lung cancer: a real-world comparative effectiveness study
Yuting Zhao, Leilei Jiang, Wei Deng, Jiayi Xiao et al.
Journal
BMC Pulmonary Medicine
Topics
Lung Cancer Diagnosis and Treatment
article
Durvalumab versus sugemalimab as consolidation therapy after definitive chemoradiotherapy for unresectable stage III non–small-cell lung cancer: a real-world comparative effectiveness study
Yuting Zhao, Leilei Jiang, Wei Deng, Jiayi Xiao, Jiahui Shan, Xiao Chang, Liuhua Long, Yue Teng, Rong Yu, Anhui Shi, Jiayi Yu, Dan Yang, Huiming Yu, Weiyan Du, Xin Dong
article en
Abstract
No abstract available for this paper.
Publication Tag
BMC Pulmonary Medicine
Institutions
Peking University (CN), Peking University Cancer Hospital (CN), Heze Municipal Hospital (CN)